These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
531 related articles for article (PubMed ID: 32966970)
1. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2. Young MJ; Clyne CD; Chapman KE J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970 [TBL] [Abstract][Full Text] [Related]
2. COVID-19, ACE2, and the cardiovascular consequences. South AM; Diz DI; Chappell MC Am J Physiol Heart Circ Physiol; 2020 May; 318(5):H1084-H1090. PubMed ID: 32228252 [TBL] [Abstract][Full Text] [Related]
3. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). Cadegiani FA; Goren A; Wambier CG Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Datta PK; Liu F; Fischer T; Rappaport J; Qin X Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005 [TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin-aldosterone system and COVID-19 infection. Alexandre J; Cracowski JL; Richard V; Bouhanick B; Ann Endocrinol (Paris); 2020 Jun; 81(2-3):63-67. PubMed ID: 32370986 [TBL] [Abstract][Full Text] [Related]
8. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV. Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Gheblawi M; Wang K; Viveiros A; Nguyen Q; Zhong JC; Turner AJ; Raizada MK; Grant MB; Oudit GY Circ Res; 2020 May; 126(10):1456-1474. PubMed ID: 32264791 [TBL] [Abstract][Full Text] [Related]
10. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2). Zemlin AE; Wiese OJ Ann Clin Biochem; 2020 Sep; 57(5):339-350. PubMed ID: 32369402 [TBL] [Abstract][Full Text] [Related]
11. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19. Malek Mahdavi A Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474 [TBL] [Abstract][Full Text] [Related]
12. Drugs acting on renin angiotensin system and use in ill patients with COVID-19. Alexandre J; Cracowski JL; Richard V; Bouhanick B; Therapie; 2020; 75(4):319-325. PubMed ID: 32553503 [TBL] [Abstract][Full Text] [Related]
13. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Danser AHJ; Epstein M; Batlle D Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682 [TBL] [Abstract][Full Text] [Related]
15. The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future. Zhang J; Wang M; Ding W; Wan J Life Sci; 2020 Sep; 257():118142. PubMed ID: 32712300 [TBL] [Abstract][Full Text] [Related]
16. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19. Sinha S; Sehgal A; Sehgal R Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071 [TBL] [Abstract][Full Text] [Related]
17. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system. Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637 [TBL] [Abstract][Full Text] [Related]
18. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective. South AM; Brady TM; Flynn JT Hypertension; 2020 Jul; 76(1):16-22. PubMed ID: 32367746 [TBL] [Abstract][Full Text] [Related]
19. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy? Aleksova A; Ferro F; Gagno G; Cappelletto C; Santon D; Rossi M; Ippolito G; Zumla A; Beltrami AP; Sinagra G J Intern Med; 2020 Oct; 288(4):410-421. PubMed ID: 32459372 [TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19. Hooper NM; Lambert DW; Turner AJ Clin Sci (Lond); 2020 Sep; 134(18):2489-2501. PubMed ID: 32990314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]